September 6, 2018 / 11:29 AM / 14 days ago

BRIEF-Oncolytics Biotech Announces A Master Clinical Supply Agreement Of An Anti-PD-L1 Checkpoint Inhibitor

Sept 6 (Reuters) - Oncolytics Biotech Inc:

* ONCOLYTICS BIOTECH® ANNOUNCES A MASTER CLINICAL SUPPLY AGREEMENT OF AN ANTI-PD-L1 CHECKPOINT INHIBITOR FOR USE IN THE COMPANY’S CLINICAL PROGRAM

* ONCOLYTICS BIOTECH INC - ENTERED INTO AGREEMENT WITH F. HOFFMANN-LA ROCHE LTD TO SUPPLY ATEZOLIZUMAB FOR USE IN CLINICAL DEVELOPMENT PROGRAM

* ONCOLYTICS BIOTECH INC - ROCHE WILL SUPPLY ATEZOLIZUMAB FOR PROPOSED CLINICAL TRIAL WITH BOTH PARTIES HAVING ACCESS TO CLINICAL DATA Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below